Gustavo Viani, Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, shared an article by Krishnan R.Patel, et al. on X:
“Should we rethink ADT omission in dose-escalated RT?
Objective:
- Evaluate whether ST-ADT + OS and biochemical control in IR-PCa.
- Include all relevant randomized controlled trials (RCTs).
Methods:
- Meta-analysis 7 RCTs (6,279),
- Endpoints: OS (primary), biochemical failure (BF) and progression-free survival (bPFS) (secondary).
Results:
- ST-ADT + OS (HR = 0.88, 5% survival gain at 10 y).
- Biochemical control (HR = 0.50, p < 0.001).
- Greater benefit with longer ADT duration & higher RT dose.
Conclusion:
- ST-ADT survival and biochemical outcomes in IR-PCa.
- Ongoing trials (NRG GU010) will refine selection.”
The Benefit of Short-Term Androgen Deprivation Therapy with Radiotherapy for Intermediate-Risk Prostate Cancer.
Authors: Krishnan R. Patel, et al.
